A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant (Q46423309)

From Wikidata

Jump to navigation Jump to search

scientific article published in April 2005

Language	Label	Description	Also known as
English	A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant	scientific article published in April 2005

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15811655

A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15811655

phase I clinical trial

0 references

0 references

Plasmodium falciparum

0 references

1 reference

based on heuristic

inferred from title

Plasmodium falciparum malaria

1 reference

based on heuristic

inferred from title

malaria vaccine

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15811655

Robin Fredric Anders

15

object named as

Robin F Anders

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15811655

author name string

Greg Lawrence

2

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15811655

Anthony Allworth

3

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15811655

Suzanne Elliott

4

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15811655

Karen Anderson

5

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15811655

Christine Rzepczyk

6

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15811655

Laura B Martin

7

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15811655

Darrin Taylor

8

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15811655

Damon P Eisen

9

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15811655

David O Irving

10

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15811655

David Pye

11

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15811655

Pauline E Crewther

12

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15811655

Anthony N Hodder

13

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15811655

Vincent J Murphy

14

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15811655

language of work or name

0 references

publication date

1 April 2005

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15811655

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15811655

23

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15811655

23

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15811655

3076-3083

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15811655

The economic and social burden of malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.040

7 January 2021

Progress and challenges for malaria vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.040

7 January 2021

High-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen 1 and induction of antibodies that inhibit erythrocyte invasion

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.040

7 January 2021

In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.040

7 January 2021

Immunisation with recombinant AMA-1 protects mice against infection with Plasmodium chabaudi

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.040

7 January 2021

Immunization with parasite-derived apical membrane antigen 1 or passive immunization with a specific monoclonal antibody protects BALB/c mice against lethal Plasmodium yoelii yoelii YM blood-stage infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.040

7 January 2021

Protective immunity induced in squirrel monkeys with recombinant apical membrane antigen-1 of Plasmodium fragile.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.040

7 January 2021

Vaccination of monkeys with recombinant Plasmodium falciparum apical membrane antigen 1 confers protection against blood-stage malaria

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.040

7 January 2021

Structure of the apical membrane antigen I (AMA-1) of Plasmodium chabaudi

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.040

7 January 2021

Integral membrane protein located in the apical complex of Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.040

7 January 2021

Differential localization of full-length and processed forms of PF83/AMA-1 an apical membrane antigen of Plasmodium falciparum merozoites.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.040

7 January 2021

The disulfide bond structure of Plasmodium apical membrane antigen-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.040

7 January 2021

Diversity of the vaccine candidate AMA-1 of Plasmodium falciparum

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.040

7 January 2021

Polymorphism in the gene encoding the apical membrane antigen-1 (AMA-1) of Plasmodium falciparum. X. Asembo Bay Cohort Project

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.040

7 January 2021

Geographical structure of diversity and differences between symptomatic and asymptomatic infections for Plasmodium falciparum vaccine candidate AMA1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.040

7 January 2021

Phase I trial in humans of an oil-based adjuvant SEPPIC MONTANIDE ISA 720.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.040

7 January 2021

Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.040

7 January 2021

A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.040

7 January 2021

Precise timing of expression of a Plasmodium falciparum-derived transgene in Plasmodium berghei is a critical determinant of subsequent subcellular localization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.040

7 January 2021

Montanide ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.040

7 January 2021

Structure of domain III of the blood-stage malaria vaccine candidate, Plasmodium falciparum apical membrane antigen 1 (AMA1)

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.040

7 January 2021

Specificity of the protective antibody response to apical membrane antigen 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.040

7 January 2021

Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.040

7 January 2021

Protective immune responses to apical membrane antigen 1 of Plasmodium chabaudi involve recognition of strain-specific epitopes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2004.09.040

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2004.09.040

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15811655

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15811655

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46423309&oldid=2220000238"